Open Access

Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury

  • Flora M. Hammond1Email author,
  • David N. Alexander2,
  • Andrew J. Cutler3,
  • Stephen D’Amico4,
  • Rachelle S. Doody5,
  • William Sauve6,
  • Richard D. Zorowitz7,
  • Charles S. Davis8,
  • Paul Shin9,
  • Fred Ledon9,
  • Charles Yonan9,
  • Andrea E. Formella9 and
  • Joao Siffert9
BMC NeurologyBMC series – open, inclusive and trusted201616:160

https://doi.org/10.1186/s12883-016-0679-z

Published: 2 September 2016

The original article was published in BMC Neurology 2016 16:89

Erratum

After publication of the original article [1], the authors noticed that there were errors in the caption of Fig. 3, and the y-axis of Fig. 6 itself.
Fig. 6

Mean CNS-LS Scores Across DM/Q Studies for PBA Secondary to Diverse Neurologic Conditions. *DM/Q 30/30 mg twice daily; †DM/Q 20/10 mg twice daily. ‡Improvement from baseline in mean CNS-LS (SE). 99-AVR-102 (4 week study comparing DM/Q to DM or Q monotherapy): End of study is the mean of the CNS-LS scores for Days 15 and 29; P = 0.001 vs. dextromethorphan comparator and P < 0.001 vs quinidine comparator. 02-AVR-106 (12 week DBPC study): End of study is the mean of the CNS-LS scores on Days 15, 29, 57, and 85; P < 0.0001 vs. placebo. 07-AVR-123 (12 week DBPC study): End of study is at Week 12 intent to treat; P < 0.05 vs. placebo. PRISM II: End of study is at Day 90/Final Visit; P < 0.001 vs. baseline in all 3 cohorts. ALS = amyotrophic lateral sclerosis; CNS-LS = Center for Neurologic Study–Lability Scale; DM/Q = dextromethorphan/quinidine; MS = multiple sclerosis; PBA = pseudobulbar affect; TBI = traumatic brain injury; SE = standard error

The following statement should not have been included in the caption of Fig. 3: “CNS-LS scores were not normalized.” The CNS-LS is a rank-order scale, and is not normalized. This statement was included erroneously and the authors intended on removing it prior to resubmission, but this was unfortunately overlooked.

Similarly, the y-axis within Fig. 6 was mislabelled. The CNS-LS scale ranges from 7 to 35, so the y-axis for Fig. 6 should start at a base score of 7 and not zero. The correct and updated version of Fig. 6, in which the data presented remain accurate and are unchanged, is published in this erratum.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Physical Medicine and Rehabilitation, Indiana University School of Medicine, Rehabilitation Hospital of Indiana
(2)
University of California
(3)
Florida Clinical Research Center, LLC
(4)
Cornerstone Medical Group
(5)
Baylor College of Medicine
(6)
TMS NeuroHealth Centers
(7)
MedStar National Rehabilitation Network
(8)
CSD Biostatistics, Inc.
(9)
Avanir Pharmaceuticals, Inc.

Reference

  1. Hammond FM, Alexander DN, Cutler AJ, D’Amico S, Doody RS, Sauve W, et al. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurol. 2016;16:89. doi:https://doi.org/10.1186/s12883-016-0609-0.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement